This brand name is authorized in Ecuador.
The drug LEMULOL D contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
QZO5366EW7 - DORZOLAMIDE HYDROCHLORIDE
|
|
Dorzolamide is a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma. |
|
2
|
UNII
P8Y54F701R - TIMOLOL MALEATE
|
|
Timolol is a non-selective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic activity. Timolol reduces intra-ocular pressure, whether or not this is associated with glaucoma. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| S01EC03 | Dorzolamide | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EC Carbonic anhydrase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 2424-MEE-1116 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.